Trevi Therapeutics (TRVI) Assets (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Assets of $179.6 million for Q1 2026, up 67.85% year-over-year from $107.0 million in Q1 2025, and down 7.15% quarter-over-quarter from $193.4 million in Q4 2025.
Trevi Therapeutics (TRVI) Assets (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $179.6 million for Q1 2026.
- In Q1 2026, Assets rose 67.85% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (up 67.85% YoY), while the FY2025 annual figure was $193.4 million, up 74.43% from the prior year.
- Assets for Q1 2026 stood at $179.6 million, down from $193.4 million in the prior quarter.
- The five-year high for Assets was $208.3 million in Q2 2025, with the low at $30.4 million in Q1 2022.
- The 5-year median for Assets is $107.0 million (2025), against an average of $116.8 million.
- The sharpest annual moves came in 2022 and 2024: Assets soared 306.26% in 2022, then slumped 32.4% in 2024.
- Trevi Therapeutics' Assets stood at $123.0 million in 2022, then dropped by 27.32% to $89.4 million in 2023, then increased by 24.05% to $110.9 million in 2024, then jumped by 74.43% to $193.4 million in 2025, then fell by 7.15% to $179.6 million in 2026.
- Business Quant data shows TRVI's Assets at $179.6 million in Q1 2026, $193.4 million in Q4 2025, and $199.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 330.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 330.52 Mn |
| Mar 31, 2026 | 179.61 Mn |
| Dec 31, 2025 | 193.44 Mn |
| Sep 30, 2025 | 199.36 Mn |
| Jun 30, 2025 | 208.34 Mn |
| Mar 31, 2025 | 107.00 Mn |
| Dec 31, 2024 | 110.90 Mn |
| Sep 30, 2024 | 68.91 Mn |
| Jun 30, 2024 | 73.81 Mn |
| Mar 31, 2024 | 78.56 Mn |
| Dec 31, 2023 | 89.40 Mn |
| Sep 30, 2023 | 95.90 Mn |
| Jun 30, 2023 | 100.98 Mn |
| Mar 31, 2023 | 116.21 Mn |
| Dec 31, 2022 | 123.02 Mn |
| Sep 30, 2022 | 128.36 Mn |
| Jun 30, 2022 | 81.41 Mn |
| Mar 31, 2022 | 30.39 Mn |
| Dec 31, 2021 | 38.48 Mn |
| Sep 30, 2021 | 31.60 Mn |